NewAmsterdam Pharma Co N.V. (NAMS): who owns it and who trades it
As of Nov 16, 2026, NAMS insiders reported 42 open-market sales worth $63.3M and 1 purchase worth $226K in the last 12 months, with 2% of the sale value made under pre-set 10b5-1 plans. The largest seller was Michael H. Davidson (CEO), with $25.3M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling NewAmsterdam Pharma
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns NAMS
194 funds and institutions reported NAMS shares worth $4.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Frazier Life Sciences Management, L.P. with 15.5%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 18.09M | 15.47% | $613M | +7% |
| Capital World Investors | 12.23M | 10.46% | $414M | +10% |
| FMR LLC (Fidelity) | 10.34M | 8.84% | $350M | +18% |
| Ra Capital Management, L.P. | 9.55M | 8.17% | $324M | No change |
| Fcpm III Services B.v. | 8.49M | 7.26% | $288M | -8% |
| Deerfield Management Company, L.P. | 4.26M | 3.65% | $145M | No change |
| Viking Global Investors LP | 4.20M | 3.60% | $142M | No change |
| Bain Capital Life Sciences Investors, LLC | 3.81M | 3.26% | $129M | -48% |
| Maverick Capital Ltd | 3.27M | 2.80% | $111M | +49% |
| Duquesne Family Office LLC | 3.07M | 2.63% | $104M | No change |
| Jupiter Topco LLC | 2.54M | 2.17% | $86M | – |
| California State Teachers Retirement System | 2.28M | 1.95% | $67.4M | +4105% |
| Medicxi Ventures Management (Jersey) Ltd | 2.21M | 1.89% | $74.9M | -17% |
| Jennison Associates LLC | 2.10M | 1.80% | $71.2M | -24% |
| Orbis Allan Gray Ltd | 1.75M | 1.49% | $59.2M | – |
| Polar Capital Holdings Plc | 1.72M | 1.48% | $58.4M | -39% |
| Capital International Investors | 1.72M | 1.47% | $58.4M | +20% |
| Goldman Sachs Group Inc | 1.54M | 1.32% | $52.4M | -21% |
| Westfield Capital Management Co LP | 1.54M | 1.31% | $52.1M | -30% |
| Castle Hook Partners LP | 1.37M | 1.17% | $46.5M | +31% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, NAMS insiders reported $226K of open-market purchases and $63.3M of sales. 2% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Johannes Jacob Pieter Kastelein | Director | Sale plan | 50,246 | $25.03 | $1.3M | Form 4 |
| Sep 14, 2026 | Michael H. Davidson | CEO | Purchase | 10,000 | $22.65 | $226K | Form 4 |
| Sep 4, 2026 | John W Smither | Director | Sale | 1,600 | $25.32 | $40.5K | Form 4 |
| Aug 24, 2026 | Johannes Jacob Pieter Kastelein | Director | Sale | 125,000 | $26.91 | $3.4M | Form 4 |
| Jul 20, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 2,915 | $31.71 | $92.4K | Form 4 |
| Jul 20, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 31,885 | $31.05 | $990K | Form 4 |
| Jul 20, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 70,200 | $29.96 | $2.1M | Form 4 |
| Jun 22, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 300 | $30.73 | $9.2K | Form 4 |
| Jun 22, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 39,700 | $30.20 | $1.2M | Form 4 |
| May 26, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 65,000 | $35.69 | $2.3M | Form 4 |
| Mar 11, 2026 | Louis G Lange | Director | Sale | 446 | $31.23 | $13.9K | Form 4 |
| Mar 11, 2026 | Louis G Lange | Director | Sale | 44,173 | $30.41 | $1.3M | Form 4 |
| Mar 9, 2026 | Johannes Jacob Pieter Kastelein | Director | Sale | 101,409 | $30.29 | $3.1M | Form 4 |
| Mar 6, 2026 | Louis G Lange | Director | Sale | 28,186 | $29.41 | $829K | Form 4 |
| Mar 6, 2026 | Johannes Jacob Pieter Kastelein | Director | Sale | 94,124 | $30.32 | $2.9M | Form 4 |
| Mar 5, 2026 | Johannes Jacob Pieter Kastelein | Director | Sale | 104,467 | $30.30 | $3.2M | Form 4 |
| Mar 2, 2026 | Michael H. Davidson | CEO | Sale | 443,707 | $33.25 | $14.8M | Form 4 |
| Feb 26, 2026 | Michael H. Davidson | CEO | Sale | 165,408 | $33.63 | $5.6M | Form 4 |
| Feb 26, 2026 | Michael H. Davidson | CEO | Sale | 17,924 | $34.44 | $617K | Form 4 |
| Feb 25, 2026 | Michael H. Davidson | CEO | Sale | 46,517 | $35.11 | $1.6M | Form 4 |
| Feb 25, 2026 | Michael H. Davidson | CEO | Sale | 10,436 | $35.96 | $375K | Form 4 |
| Feb 25, 2026 | Michael H. Davidson | CEO | Sale | 1,300 | $36.68 | $47.7K | Form 4 |
| Feb 24, 2026 | Michael H. Davidson | CEO | Sale | 61,547 | $36.13 | $2.2M | Form 4 |
| Feb 24, 2026 | Michael H. Davidson | CEO | Sale | 3,161 | $36.46 | $115K | Form 4 |
| Feb 20, 2026 | Johannes Jacob Pieter Kastelein | Director | Sale | 30,789 | $35.46 | $1.1M | Form 4 |
| Feb 20, 2026 | Johannes Jacob Pieter Kastelein | Director | Sale | 14,692 | $35.00 | $514K | Form 4 |
| Jan 28, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 32,612 | $31.80 | $1M | Form 4 |
| Jan 27, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 39,816 | $32.62 | $1.3M | Form 4 |
| Jan 26, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 34,091 | $32.77 | $1.1M | Form 4 |
| Jan 26, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 309 | $33.45 | $10.3K | Form 4 |
| Jan 23, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 25,405 | $33.44 | $850K | Form 4 |
| Jan 23, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 12,767 | $34.37 | $439K | Form 4 |
| Jan 21, 2026 | Mayur Ian Somaiya | CFO | Sale | 24,362 | $33.80 | $823K | Form 4 |
| Jan 21, 2026 | Mayur Ian Somaiya | CFO | Sale | 15,422 | $33.25 | $513K | Form 4 |
| Jan 20, 2026 | Mayur Ian Somaiya | CFO | Sale | 19,604 | $32.38 | $635K | Form 4 |
| Jan 20, 2026 | Mayur Ian Somaiya | CFO | Sale | 39,712 | $31.78 | $1.3M | Form 4 |
| Jan 20, 2026 | Mayur Ian Somaiya | CFO | Sale | 900 | $30.64 | $27.6K | Form 4 |
| Jan 5, 2026 | Johannes Jacob Pieter Kastelein | Director | Sale | 6,000 | $33.25 | $200K | Form 4 |
| Jan 5, 2026 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 2,647 | $33.25 | $88K | Form 4 |
| Jan 5, 2026 | Mayur Ian Somaiya | CFO | Sale | 5,118 | $33.25 | $170K | Form 4 |
| Dec 26, 2025 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 43,872 | $35.30 | $1.5M | Form 4 |
| Dec 24, 2025 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 26,011 | $35.68 | $928K | Form 4 |
| Dec 23, 2025 | Louise Frederika Kooij | Chief Accounting Officer | Sale | 75,117 | $36.21 | $2.7M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Michael H. Davidson | Chief Executive Officer, Director | $226K | $25.3M | Sep 14, 2026 |
| Louise Frederika Kooij | Chief Accounting Officer | – | $16.8M | Jul 20, 2026 |
| Johannes Jacob Pieter Kastelein | Chief Scientific Officer, Director | – | $15.5M | Sep 30, 2026 |
| Mayur Ian Somaiya | Chief Financial Officer | – | $3.4M | Jan 21, 2026 |
| Louis G Lange | Director | – | $2.2M | Mar 11, 2026 |
| John W Smither | Director | – | $40.5K | Sep 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
NAMS short interest
High short interest. 10.0% of NAMS shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 68%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 12.01M NAMS shares were sold short, 10.0% of the shares outstanding, down 14.9% from the report before. At the average daily volume of 1.44M shares, buying them all back would take about 8.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 12.01M | 10.05% | -15% | 1.44M | 8.3 |
| Oct 15, 2026 | 14.11M | 11.80% | -26% | 1.33M | 10.6 |
| Sep 30, 2026 | 19.05M | 15.93% | +22% | 2.03M | 9.4 |
| Sep 15, 2026 | 15.66M | 13.10% | +17% | 1.58M | 9.9 |
| Aug 31, 2026 | 13.39M | 11.20% | +6% | 1.00M | 13.4 |
| Aug 14, 2026 | 12.65M | 10.59% | +27% | 1.28M | 9.9 |
| Jul 31, 2026 | 9.96M | 8.52% | +9% | 1.02M | 9.8 |
| Jul 15, 2026 | 9.18M | 7.85% | +1% | 819,057 | 11.2 |
| Jun 30, 2026 | 9.09M | 7.78% | -1% | 1.31M | 6.9 |
| Jun 15, 2026 | 9.17M | 7.85% | +13% | 1.26M | 7.3 |
| May 29, 2026 | 8.10M | 6.93% | +13% | 1.32M | 6.2 |
| May 15, 2026 | 7.14M | 6.11% | -9% | 1.92M | 3.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
NewAmsterdam Pharma company events
NewAmsterdam Pharma filed 13 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Sep 29, 2026.
- Sep 29, 2026AnnouncementNewAmsterdam Pharma Company N.V. announced the dosing of the first patient in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer’s disease. Filing
- Sep 21, 2026AnnouncementNewAmsterdam Pharma Company N.V. along with its partner Menarini Group announced that the European Commission has granted marketing authorization for Ubeslo ® (obicetrapib 10 mg monotherapy) and Evlarco ® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination, or “FDC”) for patients with… Filing
- Aug 14, 2026LeadershipAmended an earlier report. As previously disclosed on July 22, 2026, Douglas Kling resigned as the Company’s Chief Operating Officer, effective August 14, 2026, to be appointed as the chief executive officer of another clinical-stage biotech company. Filing
- Aug 14, 2026LeadershipNewAmsterdam Pharma Company N.V. appointed Robert W. Gunning, age 55, as its principal accounting officer. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 24, 2026AnnouncementNewAmsterdam Pharma Company N.V. issued a press release announcing that the Company and the Menarini Group have received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending marketing authorization for Ubeslo® (obicetrapib… Filing
- Jul 22, 2026LeadershipDouglas Kling notified NewAmsterdam Pharma Company N.V. that he would resign as the Company’s Chief Operating Officer, effective August 14, 2026, to be appointed as the chief executive officer of another clinical-stage biotech company. Filing
- Jun 3, 2026LeadershipNewAmsterdam Pharma Company N.V. held its 2026 annual general meeting of shareholders in Amsterdam, the Netherlands. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 24, 2026LeadershipNewAmsterdam Pharma Company N.V. and Louise Kooij agreed that her employment as the Company's Chief Accounting Officer would end effective August 31, 2026 (the “Separation Date“). Filing
- Mar 2, 2026AnnouncementShared information with investors. Filing
- Feb 18, 2026ResultsReleased financial results. Filing
- Jan 9, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
NewAmsterdam Pharma financials
Famous investors that hold NAMS
6 of the 50 well-known investors we track reported holding NAMS in their latest 13F filing. The largest position is Stanley Druckenmiller's, worth $81.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Stanley Druckenmiller · Duquesne Family Office | Q3 2026 | 3.36M | $81.6M | 2.0% | +9% |
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 2.46M | $59.9M | 0.2% | -41% |
| Lee Ainslie · Maverick Capital | Q3 2026 | 1.86M | $45.1M | 0.4% | -43% |
| Israel Englander · Millennium Management | Q3 2026 | 784,158 | $19.1M | 0.0% | +56% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 277,982 | $6.8M | 0.0% | -57% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 85,007 | $2.1M | 0.0% | +7% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named NAMS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G | 7.5% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G | 7.5% |
| Nov 16, 2026 | RA Capital Management, L.P. | 13G/A | 9.9% |
| Nov 16, 2026 | RA Capital Management, L.P. | 13G/A | 9.9% |
| Nov 5, 2026 | FMR LLC | 13G/A | 10.0% |
| Nov 5, 2026 | FMR LLC | 13G/A | 10.0% |
Questions about NewAmsterdam Pharma Co N.V. (NAMS) stock
Who owns the most NAMS stock?
The largest reported owner of NewAmsterdam Pharma Co N.V. (NAMS) is Frazier Life Sciences Management, L.P., with 15.5% of the company. In total, 194 funds and institutions reported holding NAMS at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are NAMS insiders buying or selling?
In the last 12 months, NAMS insiders reported 1 open-market purchase worth $226K and 42 sales worth $63.3M. The latest trade was on Sep 30, 2026. See every trade.
What is the short interest in NAMS?
As of Oct 30, 2026, 12.01M NAMS shares were sold short, 10.0% of the shares outstanding, down 14.9% from the report before. At the average daily volume of 1.44M shares, buying them all back would take about 8.3 trading days (days to cover). See the history.
Which famous investors hold NAMS?
6 of the 50 well-known investors we track reported NAMS in their latest 13F filing, including Stanley Druckenmiller, Andreas Halvorsen, Lee Ainslie. The largest position is worth $81.6M. See all holders.
Executive pay
NewAmsterdam Pharma's chief executive was paid a total of $13.6M for the year ended Dec 31, 2025, up 111% from $6.5M the year before. In the last 12 months, NewAmsterdam Pharma's executives and directors bought $226K of stock on the open market and sold $63.3M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.